Seeking Alpha

Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY)...

Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY) exenatid BID in patients with type two diabetes. More subjects given Victoza had a blood-sugar level below 7% those who received the rival drugs. (PR)
Comments (1)
  • DMMEXMD
    , contributor
    Comments (33) | Send Message
     
    "blood sugar below 7%..." 7% of what? Does this mean the patients using Victoza were hypoglycemic? Blood sugars were 7% lower in patients taking Victorza than the others? That might be good. Blood sugars only lower than the top 7% of those taking the others? Not good. Confusing summary.
    28 Nov 2012, 03:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|